Zhang Jian-Dong, Shao Zhen-Yu
Department of Oncology, Shandong University Qianfoshan Hospital, Jinan 250014, China.
Zhonghua Zhong Liu Za Zhi. 2008 Oct;30(10):787-9.
To evaluate the efficacy and toxicity of docetaxel and capecitabine combination in the treatment of anthracycline-resistant advanced breast carcinoma.
Forty-three patients with anthracycline-resistant advanced breast carcinoma were treated with docetaxel combined with capecitabine between January 2002 and November 2004. Docetaxel was administered intravenously at a dose of 75 mg/m(2) on D1, and oral intake of capecitabine at a dose of 1600 mg/d on D1 to D14, every 21 days as a cycle. The median number of cycles was 4 (range, 4 approximately 6 cycles).
All the 43 patients had a mean follow-up of 15 months. The overall response rate was 62.8%, with a complete response rate of 20.9% and partial response rate of 44.2%. The median survival time was 15 months with a median time to progression of 7.5 months. The one-year and 2-year survival rates were 62.8% and 41.9%, respectively. The quality of life was improved in all patients. The major toxicity and adverse effects were gastrointestinal reaction and hematological toxicity.
The combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma is effective, safe and tolerable.
评估多西他赛与卡培他滨联合治疗蒽环类耐药晚期乳腺癌的疗效和毒性。
2002年1月至2004年11月期间，43例蒽环类耐药晚期乳腺癌患者接受多西他赛联合卡培他滨治疗。多西他赛于第1天静脉注射，剂量为75mg/m²，卡培他滨于第1天至第14天口服，剂量为1600mg/d，每21天为一个周期。中位周期数为4个（范围为4至6个周期）。
43例患者的平均随访时间为15个月。总缓解率为62.8%，完全缓解率为20.9%，部分缓解率为44.2%。中位生存时间为15个月，中位疾病进展时间为7.5个月。1年和2年生存率分别为62.8%和41.9%。所有患者的生活质量均有所改善。主要毒性和不良反应为胃肠道反应和血液学毒性。
多西他赛与卡培他滨联合治疗蒽环类耐药晚期乳腺癌有效、安全且耐受性良好。
Zotero 插件